Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 3 16Phase 1 4Phase NA 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Dementia 1Cognitive Dysfunction 1

Interventions

Dexamethasone 12Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Rituximab 6Prednisone 6Letrozole 6Lenalidomide 6Fluorouracil 6Cisplatin 6Carboplatin 6pembrolizumab 5Sodium Chloride 5Ropivacaine 5Human Papillomavirus Recombinant Vaccine nonavalent 5Trastuzumab 4Tamoxifen 4Standard of Care 4Propofol 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4Enoxaparin 4Doxorubicin 4Bortezomib 4Bismuth 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Gonadotropin-Releasing Hormone × 1 year × Clear all
NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Northwestern University

Phase 4 Active not recruiting
100 enrolled
Genitourinary

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡